Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma's obesity drug candidate.

For more on Immunovant’s new data, go here; for more on Sarepta’s gene therapy, go here; to learn more about Zealand’s deal ...

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming ...

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to ...

Zealand Pharma has named Roche as a development and commercialisation partner for its lead obesity candidate petrelintide, after a seven-month search. Under the deal, Zealand will receive an upfront ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

Investing.com -- Morgan Stanley upgraded its rating on Zealand Pharma (NASDAQ: ZEAL) shares to Overweight from Equal Weight, ...

BERLIN (Reuters) -Roche has entered an exclusive collaboration and licensing agreement with Danish obesity drug maker Zealand Pharma to co-develop petrelintide as an obesity therapy drug ...

Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Initiated in December 2024, the Phase 2b ZUPREME-1 trial is ...

ZURICH, March 12 (Reuters) - Roche (ROG.S), opens new tab has acquired rights to an obesity therapy by Denmark's Zealand Pharma (ZELA.CO), opens new tab in a collaboration deal worth up to $5.3 ...

ZURICH (Reuters) -Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects ...